4-chloro-6-(methylsulfonyl)quinoline-3-carboxamide | 801315-20-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-chloro-6-(methylsulfonyl)quinoline-3-carboxamide
• CAS: 801315-20-8
• 化学式: C₁₁H₉ClN₂O₃S
• 分子量: 284.723
• InChiKey: CSISCUIFXJNIKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.39
• 重原子数：
  18.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  90.12
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  4-chloro-6-(methylsulfonyl)quinoline-3-carboxamide 在 ammonium hydroxide 作用下， 以 乙腈 为溶剂， 生成 4-Amino-6-methylsulfonylquinoline-3-carboxamide
  参考文献：
  名称：

  Quinolines as a novel structural class of potent and selective PDE4 inhibitors: Optimisation for oral administration

  摘要：

  Crystallography-driven optimisation of a lead derived from similarity searching of the GSK compound collection resulted in the discovery of a series of quinoline derivatives that were highly potent and selective inhibitors of PDE4 with a good pharmacokinetic profile in the rat. Quinolines 43 and 48 have potential as oral medicines for the treatment of COPD.

  DOI：

  10.1016/j.bmcl.2009.01.045
• 作为产物：
  描述：

  在 ammonium hydroxide 作用下， 生成 4-chloro-6-(methylsulfonyl)quinoline-3-carboxamide
  参考文献：
  名称：

  Quinolines as a novel structural class of potent and selective PDE4 inhibitors: Optimisation for oral administration

  摘要：

  Crystallography-driven optimisation of a lead derived from similarity searching of the GSK compound collection resulted in the discovery of a series of quinoline derivatives that were highly potent and selective inhibitors of PDE4 with a good pharmacokinetic profile in the rat. Quinolines 43 and 48 have potential as oral medicines for the treatment of COPD.

  DOI：

  10.1016/j.bmcl.2009.01.045

文献信息

• [EN] QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] DERIVES DE QUINOLEINE UTILISES EN TANT QU'INHIBITEURS DE LA PHOSPHODIESTERASE
  申请人：GLAXO GROUP LTD

  公开号：WO2004103998A1

  公开（公告）日：2004-12-02

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20 and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了化合物的新结构，其化学式为（I）或其药用盐，其中R1、R2、R19、R20和R34如规范中所述，以及制备这些化合物的方法、含有它们的配方和它们在治疗炎症性疾病中的用途。